ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MOL Moleculin Biotech Inc

0.00
0.00 (0.00%)
- - Realtime Data
Share Name Share Symbol Market Type
Moleculin Biotech Inc TG:MOL Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

MOL Makes 4Q Losses As Falling Oil Prices Offset Strong USD Vs HUF

24/02/2015 12:19am

Dow Jones News


Moleculin Biotech (TG:MOL)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Moleculin Biotech Charts.

BUDAPEST--MOL Nyrt. (MOL.BU), one of central Europe's largest refineries and Hungary's biggest company by revenue, turned loss-making in the fourth quarter as falling oil prices offset the effects of higher production and stronger dollar against the forint, the firm's earnings report published Tuesday shows.

MAIN FACTS:

-- MOL's clean net loss was 68.6 billion forints ($272 million), compared to HUF5.2 billion profit the same period a year ago.

-- At the same time, clean earnings before interest, taxes, depreciation and amortization, or Ebitda, one of the key indicators for the sector, was up 19% on the year at HUF146 billion, versus HUF127 billion expected by eight analysts in a poll by portfolio.hu.

-- Besides a strong downstream, there was also some improvement in the upstream segment, partially a result of successful field development both in the mainland and offshore in Central Europe.

-- Loss per share was HUF778 versus HUF38 earnings per share a year earlier and a loss per share of HUF226 expected in the poll.

-- In full 2014, capital expenditure or Capex spending reached HUF532 billion ($1.97 billion) in 2014, spent on completing the firm's North Sea acquisition and a retail network buy of 44 fuel stations in the Czech Republic. This compares to a planned Capex of up to $1.9 billion.

-- Indebtedness ratio, or net gearing narrowed to 19.6% versus 16% a year ago, MOL said.

-- Zsolt Hernadi, chief executive and chairman said the company saw strong results in 2014 despite falling oil prices. He announced the firm's newest Downstream Program for 2015-2017 which is expected to bring $500 million downstream EBITDA improvement and "very strong" free cash flow generation over the coming years.

-- "In terms of acquisitions, we expect to benefit from lower oil prices; we're ready to act once the opportunity arises," Mr. Hernadi added.

-- MOL shares closed up 0.5% at HUF11,785 on the Budapest Stock Exchange Monday.

Write to Veronika Gulyas at veronika.gulyas@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Moleculin Biotech Chart

1 Year Moleculin Biotech Chart

1 Month Moleculin Biotech Chart

1 Month Moleculin Biotech Chart

Your Recent History

Delayed Upgrade Clock